Rotavirus vaccines: viral shedding and risk of transmission
Summary Rotavirus causes gastroenteritis in almost all children by 5 years of age. Immunity to rotavirus is incomplete, with potential for recurrent infections occurring throughout life. Live rotavirus vaccines have been developed for the protection of children from severe wildtype rotavirus infecti...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2008-10, Vol.8 (10), p.642-649 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 649 |
|---|---|
| container_issue | 10 |
| container_start_page | 642 |
| container_title | The Lancet infectious diseases |
| container_volume | 8 |
| creator | Anderson, Evan J, Dr |
| description | Summary Rotavirus causes gastroenteritis in almost all children by 5 years of age. Immunity to rotavirus is incomplete, with potential for recurrent infections occurring throughout life. Live rotavirus vaccines have been developed for the protection of children from severe wildtype rotavirus infections. Transmission of vaccine virus strains from vaccinated children to unvaccinated contacts harbours the potential for herd immunity, but also the risk of vaccine-derived disease in immunocompromised contacts. A review of rotavirus vaccine prelicensure studies shows that viral shedding and transmission were higher with the old tetravalent rhesus rotavirus vaccine than with the current human attenuated monovalent rotavirus vaccine and the pentavalent bovine-human reassortant vaccine. Immunocompromised contacts should be advised to avoid contact with stool from the immunised child if possible, particularly after the first vaccine dose for at least 14 days. Since the risk of vaccine transmission and subsequent vaccine-derived disease with the current vaccines is much less than the risk of wildtype rotavirus disease in immunocompromised contacts, vaccination should be encouraged. |
| doi_str_mv | 10.1016/S1473-3099(08)70231-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69678240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309908702317</els_id><sourcerecordid>69678240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-5ba2c75f910bbd929036df87a13c74f5d0b740d16c86db28162c9fe105692d2f3</originalsourceid><addsrcrecordid>eNqFkFtrFTEURgdRbK3-BGUQFH0Y3cnkqqBI8QYFwctzyOSiaedk2uyZA_335pw5VOiLT7mw9pcvq2keE3hFgIjXPwiTfdeD1i9AvZRAe9LJO81xvWYdY1ze3e9X5Kh5gHgOQCQBdr85IkpTypQ4bt5-n2a7TWXBdmudSzngm7ae7djin-B9yr9bm31bEl60U2znYjNuEmKa8sPmXrQjhkeH9aT59enjz9Mv3dm3z19PP5x1jkk-d3yw1EkeNYFh8Jpq6IWPSlrSO8ki9zBIBp4Ip4QfqCKCOh0DAS409TT2J83zNfeyTFdLwNnUAi6Mo81hWtAILaSiDCr49BZ4Pi0l126GAuGCVTcV4ivkyoRYQjSXJW1suTYEzE6t2as1O28GlNmrNbLOPTmEL8Mm-H9TB5cVeHYALDo7xmrKJbzhKAjOtdhx71cuVGfbFIpBl0J2wacS3Gz8lP5b5d2tBDemnOqjF-E64M2niUFqYA3ZZYDaJ8j-Ly4tqLo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201564474</pqid></control><display><type>article</type><title>Rotavirus vaccines: viral shedding and risk of transmission</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Anderson, Evan J, Dr</creator><creatorcontrib>Anderson, Evan J, Dr</creatorcontrib><description>Summary Rotavirus causes gastroenteritis in almost all children by 5 years of age. Immunity to rotavirus is incomplete, with potential for recurrent infections occurring throughout life. Live rotavirus vaccines have been developed for the protection of children from severe wildtype rotavirus infections. Transmission of vaccine virus strains from vaccinated children to unvaccinated contacts harbours the potential for herd immunity, but also the risk of vaccine-derived disease in immunocompromised contacts. A review of rotavirus vaccine prelicensure studies shows that viral shedding and transmission were higher with the old tetravalent rhesus rotavirus vaccine than with the current human attenuated monovalent rotavirus vaccine and the pentavalent bovine-human reassortant vaccine. Immunocompromised contacts should be advised to avoid contact with stool from the immunised child if possible, particularly after the first vaccine dose for at least 14 days. Since the risk of vaccine transmission and subsequent vaccine-derived disease with the current vaccines is much less than the risk of wildtype rotavirus disease in immunocompromised contacts, vaccination should be encouraged.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(08)70231-7</identifier><identifier>PMID: 18922486</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Biological and medical sciences ; Disease transmission ; Gastroenteritis ; Herd immunity ; Human viral diseases ; Humans ; Immunization ; Infectious Disease ; Infectious diseases ; Medical sciences ; Risk Factors ; Rotavirus - physiology ; Rotavirus Infections - immunology ; Rotavirus Infections - prevention & control ; Rotavirus Infections - transmission ; Rotavirus Infections - virology ; Rotavirus Vaccines - adverse effects ; Vaccines ; Viral diseases ; Viral diseases of the digestive system ; Virus Shedding - physiology</subject><ispartof>The Lancet infectious diseases, 2008-10, Vol.8 (10), p.642-649</ispartof><rights>Elsevier Ltd</rights><rights>2008 Elsevier Ltd</rights><rights>2008 INIST-CNRS</rights><rights>Copyright Elsevier Limited Oct 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-5ba2c75f910bbd929036df87a13c74f5d0b740d16c86db28162c9fe105692d2f3</citedby><cites>FETCH-LOGICAL-c475t-5ba2c75f910bbd929036df87a13c74f5d0b740d16c86db28162c9fe105692d2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/201564474?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20655966$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18922486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anderson, Evan J, Dr</creatorcontrib><title>Rotavirus vaccines: viral shedding and risk of transmission</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Summary Rotavirus causes gastroenteritis in almost all children by 5 years of age. Immunity to rotavirus is incomplete, with potential for recurrent infections occurring throughout life. Live rotavirus vaccines have been developed for the protection of children from severe wildtype rotavirus infections. Transmission of vaccine virus strains from vaccinated children to unvaccinated contacts harbours the potential for herd immunity, but also the risk of vaccine-derived disease in immunocompromised contacts. A review of rotavirus vaccine prelicensure studies shows that viral shedding and transmission were higher with the old tetravalent rhesus rotavirus vaccine than with the current human attenuated monovalent rotavirus vaccine and the pentavalent bovine-human reassortant vaccine. Immunocompromised contacts should be advised to avoid contact with stool from the immunised child if possible, particularly after the first vaccine dose for at least 14 days. Since the risk of vaccine transmission and subsequent vaccine-derived disease with the current vaccines is much less than the risk of wildtype rotavirus disease in immunocompromised contacts, vaccination should be encouraged.</description><subject>Biological and medical sciences</subject><subject>Disease transmission</subject><subject>Gastroenteritis</subject><subject>Herd immunity</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Risk Factors</subject><subject>Rotavirus - physiology</subject><subject>Rotavirus Infections - immunology</subject><subject>Rotavirus Infections - prevention & control</subject><subject>Rotavirus Infections - transmission</subject><subject>Rotavirus Infections - virology</subject><subject>Rotavirus Vaccines - adverse effects</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Viral diseases of the digestive system</subject><subject>Virus Shedding - physiology</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkFtrFTEURgdRbK3-BGUQFH0Y3cnkqqBI8QYFwctzyOSiaedk2uyZA_335pw5VOiLT7mw9pcvq2keE3hFgIjXPwiTfdeD1i9AvZRAe9LJO81xvWYdY1ze3e9X5Kh5gHgOQCQBdr85IkpTypQ4bt5-n2a7TWXBdmudSzngm7ae7djin-B9yr9bm31bEl60U2znYjNuEmKa8sPmXrQjhkeH9aT59enjz9Mv3dm3z19PP5x1jkk-d3yw1EkeNYFh8Jpq6IWPSlrSO8ki9zBIBp4Ip4QfqCKCOh0DAS409TT2J83zNfeyTFdLwNnUAi6Mo81hWtAILaSiDCr49BZ4Pi0l126GAuGCVTcV4ivkyoRYQjSXJW1suTYEzE6t2as1O28GlNmrNbLOPTmEL8Mm-H9TB5cVeHYALDo7xmrKJbzhKAjOtdhx71cuVGfbFIpBl0J2wacS3Gz8lP5b5d2tBDemnOqjF-E64M2niUFqYA3ZZYDaJ8j-Ly4tqLo</recordid><startdate>20081001</startdate><enddate>20081001</enddate><creator>Anderson, Evan J, Dr</creator><general>Elsevier Ltd</general><general>Lancet Publishing Group</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20081001</creationdate><title>Rotavirus vaccines: viral shedding and risk of transmission</title><author>Anderson, Evan J, Dr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-5ba2c75f910bbd929036df87a13c74f5d0b740d16c86db28162c9fe105692d2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Disease transmission</topic><topic>Gastroenteritis</topic><topic>Herd immunity</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Risk Factors</topic><topic>Rotavirus - physiology</topic><topic>Rotavirus Infections - immunology</topic><topic>Rotavirus Infections - prevention & control</topic><topic>Rotavirus Infections - transmission</topic><topic>Rotavirus Infections - virology</topic><topic>Rotavirus Vaccines - adverse effects</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Viral diseases of the digestive system</topic><topic>Virus Shedding - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anderson, Evan J, Dr</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anderson, Evan J, Dr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rotavirus vaccines: viral shedding and risk of transmission</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2008-10-01</date><risdate>2008</risdate><volume>8</volume><issue>10</issue><spage>642</spage><epage>649</epage><pages>642-649</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Summary Rotavirus causes gastroenteritis in almost all children by 5 years of age. Immunity to rotavirus is incomplete, with potential for recurrent infections occurring throughout life. Live rotavirus vaccines have been developed for the protection of children from severe wildtype rotavirus infections. Transmission of vaccine virus strains from vaccinated children to unvaccinated contacts harbours the potential for herd immunity, but also the risk of vaccine-derived disease in immunocompromised contacts. A review of rotavirus vaccine prelicensure studies shows that viral shedding and transmission were higher with the old tetravalent rhesus rotavirus vaccine than with the current human attenuated monovalent rotavirus vaccine and the pentavalent bovine-human reassortant vaccine. Immunocompromised contacts should be advised to avoid contact with stool from the immunised child if possible, particularly after the first vaccine dose for at least 14 days. Since the risk of vaccine transmission and subsequent vaccine-derived disease with the current vaccines is much less than the risk of wildtype rotavirus disease in immunocompromised contacts, vaccination should be encouraged.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>18922486</pmid><doi>10.1016/S1473-3099(08)70231-7</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2008-10, Vol.8 (10), p.642-649 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69678240 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Biological and medical sciences Disease transmission Gastroenteritis Herd immunity Human viral diseases Humans Immunization Infectious Disease Infectious diseases Medical sciences Risk Factors Rotavirus - physiology Rotavirus Infections - immunology Rotavirus Infections - prevention & control Rotavirus Infections - transmission Rotavirus Infections - virology Rotavirus Vaccines - adverse effects Vaccines Viral diseases Viral diseases of the digestive system Virus Shedding - physiology |
| title | Rotavirus vaccines: viral shedding and risk of transmission |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T12%3A43%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rotavirus%20vaccines:%20viral%20shedding%20and%20risk%20of%20transmission&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Anderson,%20Evan%20J,%20Dr&rft.date=2008-10-01&rft.volume=8&rft.issue=10&rft.spage=642&rft.epage=649&rft.pages=642-649&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(08)70231-7&rft_dat=%3Cproquest_cross%3E69678240%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201564474&rft_id=info:pmid/18922486&rft_els_id=S1473309908702317&rfr_iscdi=true |